cigna glp-1 coverage news today dropping obesity drug for employees (CI) Health insurer Cigna will stop
Description
Weight loss and persistence with liraglutide 3.0 mg by obesity class in the real-world effectiveness study in Canada
Hello Friends!
The FDA significantly increased its compliance activity surrounding advertising for compounded drugs in 2025, and recent remarks from an FDA official highlighted the agencys concerns about claims that state or imply the equivalence of compounded drugs to approved drugs.
Una reciente revisin narrativa analiza los efectos del agonismo del receptor de incretina particularmente de los agonistas del receptor del pptido similar al glucagn tipo 1 (GLP-1RA) y de los agonistas duales de los receptores GLP-1 y GIP (GLP-1/GIPRA) sobre la masa libre de grasa (MLG) y la aptitud cardiorrespiratoria
